{"id":"encapsulated-fmt","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal symptoms (abdominal pain, bloating, diarrhea)"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Flatulence"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fecal microbiota transplantation (FMT) works by introducing beneficial bacterial communities from screened donor stool into the patient's gut, where they colonize and rebalance the dysbiotic microbiome. The encapsulation protects the live bacteria from stomach acid and bile, allowing them to survive transit and establish in the lower intestine. This microbial restoration can reduce pathogenic organisms, restore metabolic function, and modulate immune responses.","oneSentence":"Encapsulated FMT delivers a standardized consortium of live bacteria directly to the colon to restore a healthy microbiome composition.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:46:22.548Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Clostridioides difficile infection (recurrent or refractory)"},{"name":"Inflammatory bowel disease (Crohn's disease or ulcerative colitis)"}]},"trialDetails":[{"nctId":"NCT07490054","phase":"PHASE1","title":"Intestinal Microbiota Transplantation in Patients With Chronic Heart Failure","status":"RECRUITING","sponsor":"Melana Yuzefpolskaya, MD","startDate":"2025-09-01","conditions":"Chronic Heart Failure","enrollment":40},{"nctId":"NCT06461208","phase":"PHASE3","title":"A PROspective Faecal MIcrobiota tranSplantation Trial to Improve outcomEs in Patients With Cirrhosis","status":"RECRUITING","sponsor":"King's College London","startDate":"2023-06-21","conditions":"Liver Cirrhosis","enrollment":300},{"nctId":"NCT03843385","phase":"PHASE3","title":"Transfer of FRozen Encapsulated Multidonor Stool Filtrate for Active Ulcerative COlitis","status":"RECRUITING","sponsor":"Andreas Stallmach","startDate":"2023-01-31","conditions":"Ulcerative Colitis, Inflammatory Bowel Diseases","enrollment":129},{"nctId":"NCT06499896","phase":"PHASE2","title":"Healthy-donor Microbiome MTP-101-C in Steroid Relapse/Refractory Immune-related Cutaneous Adverse Events (irCAEs) and Immune-mediated Colitis (IMC)","status":"RECRUITING","sponsor":"Diwakar Davar","startDate":"2025-01-23","conditions":"Immune-mediated Colitis (IMC), Immune-related Dermatitis","enrollment":30},{"nctId":"NCT07017946","phase":"PHASE1, PHASE2","title":"Intestinal Microbiome Transplant in ALS","status":"RECRUITING","sponsor":"Duke University","startDate":"2026-01-27","conditions":"Amyotrophic Lateral Sclerosis ALS","enrollment":20},{"nctId":"NCT07319364","phase":"PHASE1","title":"A Real-World Study of Fecal Transplants for Cancer Therapy Side Effects","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-09-01","conditions":"Fecal Microbiota Transplantation (FMT), Gastrointestinal Neoplasms, Antineoplastic Agents","enrollment":90},{"nctId":"NCT06022406","phase":"PHASE2","title":"Fecal Microbiota Translantation (FMT) to Reduce Inflammation in PLWH: The Gutsy Pilot Study","status":"COMPLETED","sponsor":"Jean-Pierre Routy","startDate":"2024-07-31","conditions":"HIV-1-infection","enrollment":20},{"nctId":"NCT07120490","phase":"NA","title":"STOP-CDI: Efficacy of Fecal Microbiota Transplantation vs Fidaxomicin vs Vancomycin in Treating and Preventing Relapse of Clostridioides Difficile Infection","status":"NOT_YET_RECRUITING","sponsor":"Medical University of Warsaw","startDate":"2025-10","conditions":"Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, Fecal Microbiota Transplantation (FMT)","enrollment":424},{"nctId":"NCT03948919","phase":"PHASE1","title":"Fecal Transplant for Ulcerative Colitis","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2019-07-31","conditions":"Ulcerative Colitis","enrollment":26},{"nctId":"NCT07083882","phase":"PHASE2","title":"Faecal Autologous Capsule Transplantation for Type 1 Diabetes Mellitus","status":"RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2025-09","conditions":"Type 1 Diabetes Mellitis, Type 1 Diabetes (T1D), Fecal Microbiota Therapy (FMT)","enrollment":110},{"nctId":"NCT05035342","phase":"PHASE3","title":"Fecal Transplantation to Eradicate Colonizing Emergent Superbugs","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-01-11","conditions":"Enterobacteriaceae Infections, Fecal Microbiota Transplantation","enrollment":214},{"nctId":"NCT06201182","phase":"NA","title":"Efficacy of Fecal Microbiota Transplantation (FMT) in Irritable Bowel Syndrome (IBS)","status":"RECRUITING","sponsor":"Thammasat University","startDate":"2020-08-19","conditions":"Irritable Bowel Syndrome","enrollment":45},{"nctId":"NCT04968951","phase":"EARLY_PHASE1","title":"Refined Fecal Microbiota Transplantation (FMT) for Ulcerative Colitis (UC)","status":"TERMINATED","sponsor":"Ari M Grinspan","startDate":"2021-11-10","conditions":"Ulcerative Colitis, FMT, Fecal Microbiota Transplant","enrollment":4},{"nctId":"NCT04884971","phase":"PHASE1","title":"Microbiota Transplant Therapy for Pulmonary Arterial Hypertension: Early Safety and Feasibility Study","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2021-11-03","conditions":"Pulmonary Arterial Hypertension","enrollment":11},{"nctId":"NCT04805879","phase":"PHASE2, PHASE3","title":"The Safety and Efficacy of Fecal Microbiota Transplantation in a Population With Major Depressive Disorder","status":"UNKNOWN","sponsor":"University of Calgary","startDate":"2021-03-04","conditions":"Depression, Treatment Resistant Depression","enrollment":80},{"nctId":"NCT02330653","phase":"PHASE1, PHASE2","title":"Fecal Microbiota Transplant (FMT) in Pediatric Active Ulcerative Colitis and Pediatric Active Crohn's Colitis","status":"COMPLETED","sponsor":"Stacy A. Kahn","startDate":"2015-11","conditions":"Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease","enrollment":15},{"nctId":"NCT04960306","phase":"PHASE3","title":"Fecal Filtrate as a Treatment Option of Multiple Recurrent Clostridioides Difficile Infection","status":"UNKNOWN","sponsor":"University of Pecs","startDate":"2023-11-01","conditions":"Clostridium Difficile Infection, Recurrent Clostridium Difficile Infection","enrollment":238},{"nctId":"NCT05622123","phase":"PHASE2","title":"BetaFIT Study: Beta Cell Imaging After Faecal mIcrobiota Transplantation","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2023-02-23","conditions":"Type 1 Diabetes","enrollment":20},{"nctId":"NCT02801656","phase":"PHASE3","title":"Fecal Microbiota Transplantation for Primary Clostridium Difficile Diarrhea","status":"WITHDRAWN","sponsor":"Memorial University of Newfoundland","startDate":"2020-12-01","conditions":"Clostridium Difficile","enrollment":""},{"nctId":"NCT05323162","phase":"NA","title":"Encapsulated Faecal Microbiota Transplantation to Preserve Residual Beta Cell Function in Type 1 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Nordin Hanssen","startDate":"2022-04","conditions":"Type 1 Diabetes","enrollment":10},{"nctId":"NCT02960074","phase":"PHASE1","title":"Evaluating the Safety and Efficacy of Oral Encapsulated Fecal Microbiota Transplant in Peanut Allergic Patients","status":"COMPLETED","sponsor":"Rima Rachid","startDate":"2017-03-03","conditions":"Peanut Allergy","enrollment":15},{"nctId":"NCT03712722","phase":"","title":"Fecal Microbiota Transplantation (FMT) for Clostridium Difficile","status":"UNKNOWN","sponsor":"University of Aarhus","startDate":"2018-10-01","conditions":"Clostridium Difficile Infection","enrollment":100},{"nctId":"NCT03621657","phase":"PHASE2","title":"The GRAFT Study: Gut RecolonizAtion by Fecal Transplantation","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2019-03-21","conditions":"Clostridium Difficile Infection, C.Difficile Diarrhea, CDI","enrollment":1},{"nctId":"NCT03998423","phase":"PHASE1","title":"Oral Fecal Microbiota Transplant Feasibility Study in Alzheimer's Disease","status":"TERMINATED","sponsor":"University of Wisconsin, Madison","startDate":"2019-11-14","conditions":"Alzheimer Disease","enrollment":5},{"nctId":"NCT03329560","phase":"PHASE1","title":"Safety of FMT Using Oral Encapsulated PRIM-DJ2727 in HIV","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2018-04-12","conditions":"HIV-1-infection","enrollment":6},{"nctId":"NCT03063437","phase":"PHASE2","title":"A Trial of Encapsulated Fecal Microbiota for Vancomycin Resistant Enterococcus Decolonization","status":"COMPLETED","sponsor":"Microbiome Health Research Institute","startDate":"2017-08-17","conditions":"Antibiotic Resistant Strain","enrollment":9},{"nctId":"NCT02741518","phase":"PHASE1, PHASE2","title":"Fecal Microbiota Transplantation for the Treatment of Obesity","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2017-04-01","conditions":"Obesity","enrollment":22},{"nctId":"NCT02530385","phase":"PHASE1, PHASE2","title":"Fecal Microbiota Transplant for Improvement of Metabolism","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2016-06","conditions":"Obesity","enrollment":24},{"nctId":"NCT02343328","phase":"PHASE1","title":"Placebo Controlled Study of Fecal Microbiota Transplant (FMT) for a First or Second Episode of C. Difficile Infection in Adults Using a Frozen Encapsulated Inoculum","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2015-01","conditions":"Clostridium Difficile","enrollment":3},{"nctId":"NCT01914731","phase":"PHASE1","title":"Fecal Microbiota Transplant for Relapsing Clostridium Difficile Infection in Adults and Children Using a Frozen Encapsulated Inoculum","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2013-08","conditions":"Clostridium Difficile Infection","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":21,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Encapsulated FMT","genericName":"Encapsulated FMT","companyName":"King's College London","companyId":"king-s-college-london","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Encapsulated FMT delivers a standardized consortium of live bacteria directly to the colon to restore a healthy microbiome composition. Used for Clostridioides difficile infection (recurrent or refractory), Inflammatory bowel disease (Crohn's disease or ulcerative colitis).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}